WO2001088532A2 - Improved assay techniques using nematode worms - Google Patents

Improved assay techniques using nematode worms Download PDF

Info

Publication number
WO2001088532A2
WO2001088532A2 PCT/IB2001/001058 IB0101058W WO0188532A2 WO 2001088532 A2 WO2001088532 A2 WO 2001088532A2 IB 0101058 W IB0101058 W IB 0101058W WO 0188532 A2 WO0188532 A2 WO 0188532A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
sample
paralysing
nematodes
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/001058
Other languages
French (fr)
Other versions
WO2001088532A3 (en
Inventor
Philippe Verwaerde
Gwladys Cuvillier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Devgen NV
Original Assignee
Devgen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Devgen NV filed Critical Devgen NV
Priority to JP2001584877A priority Critical patent/JP2003533696A/en
Priority to EP01936742A priority patent/EP1282816A2/en
Priority to US10/276,453 priority patent/US7083947B2/en
Priority to AU2001262601A priority patent/AU2001262601A1/en
Publication of WO2001088532A2 publication Critical patent/WO2001088532A2/en
Publication of WO2001088532A3 publication Critical patent/WO2001088532A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
    • G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
    • G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the present invention relates to improved techniques for performing assays using nematode worms, such as nematodes worms from the genus Caernorhabditis .
  • the invention relates to improved techniques for performing assays using nematode worms in multi-well plate format.
  • Such multi-well plate assays may be automated (i.e. using suitable robotics) and/or may be configured for (compound) screening medium to high throughput .
  • C. elegans As described in these applications, one of the main advantages of such assays involving the use of C. elegans is that they can be carried out in multi-well plate format (with each well usually containing a sample of between 2 and 500, and usually between 20 and 200 nematodes per well) . Also because of this, assays involving the use of C. elegans can be carried out in an automated fashion, i.e. using suitable robotics (as are described in the aforementioned applications and/or as may be commercially available) .
  • assays involving the use of C. elegans may be automated, such assays are also ideally suited for screening of libraries of chemical compounds, in particular at medium to high throughput.
  • Such automated screens may for instance be used in the discovery and/or development of new compounds (e.g. small molecules) for pharmaceutical, verterinary or agrochemical/pesticidal (e.g. insecticidal and/or nematicidal) use.
  • the nematodes are incubated in suitable vessel or container - such as a compartment or well of a multi-well plate - on a suitable medium (which may be a solid, semi-solid, viscous or liquid medium, with liquid and viscous media usually being preferred for assays in multi-well plate format) .
  • a suitable medium which may be a solid, semi-solid, viscous or liquid medium, with liquid and viscous media usually being preferred for assays in multi-well plate format
  • the nematodes are then contacted with the compound (s) to be tested, e.g. by adding the compound to the medium containing the worms.
  • a suitable incubation time i.e. sufficient for the compound to have its effect - if any - on the nematodes
  • the worms are then subjected to a suitable detection technique, i.e. to measure/determine a signal that is representative for the influence of the compound (s) to be tested on the nematode
  • such a detection technique involves a non-visual detection method, such as measurement of fluorescence or another optical method, measurement of a particular marker (either associated with worms or associated with the medium) such as autonomous fluorescent proteins (AFP's) such as green fluorescent proteins (GFP's), aequorin, alkaline phosphatase, luciferase, Beta-glucoronidase, Beta- lactamase, Beta-galactosidase, acetohydroxyacid, chloramphenicol acetyl transferase, horse radish peroxidase, nopaline synthase, or octapine synthase.
  • AFP's autonomous fluorescent proteins
  • GFP's green fluorescent proteins
  • aequorin alkaline phosphatase
  • luciferase beta-glucoronidase
  • Beta- lactamase Beta- lactamase
  • Beta-galactosidase acetohydroxyacid
  • the invention relates to a method • for measuring/determining at least one signal generated by and/or associated with a sample of nematode worms, which nematode worms are kept in a suitable medium in a suitable vessel or container, said method comprising the steps of: exposing the sample of nematodes to at least one compound which paralyses or kills the nematodes present in the sample; and measuring/determining the at least one signal.
  • the sample of nematodes can be kept - e.g.
  • a multi-well plate such as standard 6, 24, 48, 96, 384, 1536, or 3072 well plates (in which each well of the multi-well plate may contain a separate sample of worms) .
  • a multi-well plate such as standard 6, 24, 48, 96, 384, 1536, or 3072 well plates (in which each well of the multi-well plate may contain a separate sample of worms) .
  • Such plates and general techniques and apparatus for maintaining/handling nematode worms in such multi-well plate format are well known in the art, for instance from the applications mentioned hereinabove.
  • the sample of nematodes may be kept in or on any suitable medium - including but not limited to solid and semi-solid media - but is preferably kept in a suitable liquid or viscous medium (e.g. with a viscosity at the temperature of the assay that is equal to a greater than the viscosity of M9 medium, as measured by a suitable technique, such as an Ubbelohde, Ostwald and/or Brookfield viscosimeter) .
  • suitable media for growing/maintaining nematode worms are well known in the art, for instance from the applications mentioned hereinabove, and include M9.
  • the sample of nematodes may comprise any suitable number of worms, depending on the size of the container/vessel used. Usually, the sample will comprise between 2 and 500, in preferably between 3 and 300, more preferably between 5 and 200, even more preferably between 10 and 100 nematodes.
  • each well usually contains between 15 and 75 worms, such as 20 to 50 worms.
  • the medium may further contain all factors, compounds and/or nutrients required to carry out the assay and/or required for the survival, maintenance and/or growth of the worms. For this, reference is again made to the prior art, such as the applications referred to above.
  • the medium also contains a suitable source of food for the worms (such as bacteria) .
  • a suitable source of food for the worms such as bacteria. This not only ensures/promotes survival and/or growth of the nematodes, but may also trigger or increase pharynx pumping by the nematodes, and may therefore facilitate assays based on and/or requiring (at least some degree of) pharynx pumping.
  • the at least one compound which paralyses the nematodes may be any suitable compound which (at the concentration added to the sample of nematodes) paralyses the worms, such that they collect at the bottom of the container.
  • said compound is chosen from Ethanol, methanol, DMSO, Levamisole, aldicarb, azide, trichlorphon, muscimole, carbosulfan, carbofuran, carbosasos, most preferably ivermectine.
  • the paralysing compound is added to the sample of nematode worms (e.g. to the medium/container or well containing said sample) in a concentration such that - due to the paralysing effect of the compound (and usually also due to gravity) - the worms collect at a specific part of the container or well, which is usually the part from which the signal of interest generated by/associated with the sample of nematodes is measured/determined. Usually this will be the bottom half, bottom part or bottom tip of the container or well.
  • Suitable concentrations of paralysing compound may easily be determined by the skilled person, and - depending on the compound (s) used - may be between 0.01 and 10.000 micromolar, preferably between 0.1 and 1000 micromolar, in particular between 1 and 100 micromolar. For instance, for ivermectine, a suitable concentration will usually be between 0.5 and 50 micromolar, in particular between 1 and 10 micromolar, such as 3 micromolar.
  • step b) above the worms are exposed to the at least one paralysing compound for a time that is sufficient for the worms - due to the paralysing effect of the compound (and usually also due to gravity) - to collect at a specific part of the container or well, e.g. at the bottom of the well.
  • Suitable exposure times may easily be determined by the skilled person, and - depending on the compound (s) used - may be between one minute and four hours, preferably between 5 minutes and two hours, more preferably between ten minutes and one hour, such as between 20 minutes and 45 minutes.
  • the signal of interest generated by/associated with the sample of nematodes is measured/determined. This may be any suitable signal, such as fluorescence or another optical signal.
  • the method of the invention may be used to improve the reliability, reproducibility and/or robustness of any assay involving the use of nematode worms - and in particular nematode worms of the genus Caenorhabdi tis such as C. elegans or C. briggsae - such as the assays described in the applications mentioned above and other in other applications by applicant.
  • this may simply be achieved by adding to the method/protocol for carrying out said known assay, a step of adding the paralysing compound (i.e. step b) above), in the manner described above, and prior to measurement of the signal of interest.
  • the invention is particularly suited as an improvement for such known assays when they are carried out in a multi-well plate format, in liquid or viscous medium, and/or in an automated fashion.
  • the invention may in particular be used to improve assays in which the effect of one or more compounds or other factors on (the signal generated by/associated with) the sample of nematode worms is determined, and some of these assays are also described in the applications referred to above.
  • the method of the invention will comprise the further step of: exposing the sample of nematode worms to at least one compound to be tested.
  • the further conditions for this step a) - such as suitable concentrations of compound and times for such exposures - will depend on the specific assay used and on the compound (s) to be tested. Reference is again made to the prior art, such as the applications referred to above.
  • the compounds may be tested at any suitable concentration or range of concentrations (e.g. to establish a dose response curve) .
  • suitable concentrations may be in the range of between 0.001 and 10.000 micromolar, preferably between 0.01 and 1000 micromolar, in particular between 0.05 and 500 micromolar, although the invention is not limited thereto.
  • Suitable contact times of the compound and the (sample of) nematodes may be between 10 seconds and 48 hours, preferably between 1 minute and 36 hours, and may for instance be between 30 minutes and 24 hours. For instance, incubation of about 1 hr to overnight (e.g. about 16 hours) may be used.
  • the invention relates to the use of at least one paralysing compound - as described above - in improving the reliability, reproducibility and/or robustness of an assays involving the use of ( a sample of) nematode worms.
  • the paralysing compound, its use and the assays involving the use of nematode worms are preferably as further described above.
  • An other application of this new invention related to the detection of the defecation rate, in which the improvement results in a method to identify improved signal detection in multi-well assays, using dispensed • nematodes, wherein prior to detecting a signal indicating defecation by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates.
  • the invention is applied to egg laying, in which the improvement results in a method to identify improved signal detection in multi-well assays, using dispensed nematodes, wherein prior to detecting a signal indicating egg laying by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates.
  • the invention is applied to fatty acid uptake, and cholesterol uptake, in which the improvement results in a method to identify improved signal detection in multi- well assays, using dispensed nematodes, wherein prior to detecting a signal indicating for lipid uptake or cholesterol uptake by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi-well plates.
  • a method is described to identify genetic mutations, using nematode worms dispersed in multi-well assay plates, contacted with a mutagen, wherein prior to detecting a signal indicating phenotypic, physiologic, behavioral or biochemical changes by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi-well plates.
  • the major disadvantage of these methods is the laborious task to select for the desired mutants.
  • the method described here allows to select in an efficient and fast way for a mutation with the desired phenotypic, physiologic, behavioral or • biochemical change.
  • the detection methods are the same as these described above and refer to the pharynx pumping assay, the defecation assay, the egg laying assay, the fatty acid uptake assay.
  • the further application of this invention is a method to identify RNAi knock-outs, using nematode worms dispersed in multi-well assay plates, are feeded with bacteria that express high quantities of dsRNA, wherein prior to detecting a signal indicating phenotypic, physiologic, behavioral or biochemical changes by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Improved techniques for performing assays using nematode worms, such as nematode worms from the genus Caenorhabditis. The assays generally comprise exposing nematodes to at least one compound which paralyses or kills the nematodes.

Description

Improved assay techniques -using nematode worms.
The present invention relates to improved techniques for performing assays using nematode worms, such as nematodes worms from the genus Caernorhabditis .
In particular, the invention relates to improved techniques for performing assays using nematode worms in multi-well plate format. Such multi-well plate assays may be automated (i.e. using suitable robotics) and/or may be configured for (compound) screening medium to high throughput .
Other aspects, embodiments and advantages will become clear from the further description hereinbelow.
Techniques for performing in vivo assays using the nematode worm Caenorhabditis elegans (C. elegans) as a model organism have been described in the art, most notably in the following applications by applicant:PCT/EP99/09710 published as WO 00/34438 (15
June 2000 PCT/EP99/04718, published as WO/00/01846 ( 15 Jan. 2000 PCT/IB00/00575, published as WO 00/63427 (26
Oct. 2000 PCT/IB00/00557, published as WO 00/63425 (26
Oct. 2000 PCT/IB00/00558, published as WO 00/63426 (26
Oct. 2000 as well as for instance PCT/US98/10080 (published on 19-11-1998 as WO 98/51351), PCT/US99/13650, PCT/US99/01361 (published on 29-07-1999 as WO99/37770), and PCT/EP00/05102) .
As described in these applications, one of the main advantages of such assays involving the use of C. elegans is that they can be carried out in multi-well plate format (with each well usually containing a sample of between 2 and 500, and usually between 20 and 200 nematodes per well) . Also because of this, assays involving the use of C. elegans can be carried out in an automated fashion, i.e. using suitable robotics (as are described in the aforementioned applications and/or as may be commercially available) .
Furthermore, because assays involving the use of C. elegans may be automated, such assays are also ideally suited for screening of libraries of chemical compounds, in particular at medium to high throughput. Such automated screens may for instance be used in the discovery and/or development of new compounds (e.g. small molecules) for pharmaceutical, verterinary or agrochemical/pesticidal (e.g. insecticidal and/or nematicidal) use.
Generally, in the assays described above, the nematodes are incubated in suitable vessel or container - such as a compartment or well of a multi-well plate - on a suitable medium (which may be a solid, semi-solid, viscous or liquid medium, with liquid and viscous media usually being preferred for assays in multi-well plate format) . The nematodes are then contacted with the compound (s) to be tested, e.g. by adding the compound to the medium containing the worms. After a suitable incubation time (i.e. sufficient for the compound to have its effect - if any - on the nematodes) , the worms are then subjected to a suitable detection technique, i.e. to measure/determine a signal that is representative for the influence of the compound (s) to be tested on the nematode worms, which may then be used as a measure for the activity of the compound (s) in the in vivo assay.
Often, in particular for automated assays, such a detection technique involves a non-visual detection method, such as measurement of fluorescence or another optical method, measurement of a particular marker (either associated with worms or associated with the medium) such as autonomous fluorescent proteins (AFP's) such as green fluorescent proteins (GFP's), aequorin, alkaline phosphatase, luciferase, Beta-glucoronidase, Beta- lactamase, Beta-galactosidase, acetohydroxyacid, chloramphenicol acetyl transferase, horse radish peroxidase, nopaline synthase, or octapine synthase. For example, for automated assays carried out in multi-well plates, so called (multi-well) "plate readers" may be used for detecting/measuring said signal.
For a further description of the above and other assay techniques involving the use of nematodes as a model organism, reference is made to the prior art, such as the applications by applicant referred to above.
Although the above assay techniques are well established in the art - and have been successfully used by applicant to screen libraries comprising tens-of- thousands chemical compounds - there is a constant need to improve these assays, for example to make them even more robust and reliable. The present invention provides such an improvement, in particular in the following regard: As assays based on C . elegans involve the use of a living organism, which can move around in the medium in which it is kept/maintained, the distribution of worms may not be uniform throughout the medium/container. This uneven distribution of worms may interfere with the signal that is measured and thus may affect the reliability of the assay.
This may in particular be a problem with assays that are carried out in multi-well plate format, on the one hand because such assays are often carried out in liquid or viscous medium (making it easier for the worms to move around, also in three dimensions) , but also because the automated plate readers used in such assays often measure the signal from only part of the well (e.g. from the bottom part/halve of the well, from the bottom tip of the well, and/or through the central vertical axis of the well) .
It has now been found that this problem may be solved - and thus the reliability of assays involving the use of C. elegans improved - by adding to the medium in which the nematodes are kept - e.g. after the nematodes have been suitably exposed to the compound (s) to be tested - at least one substance that paralyses the nematodes. Due to this paralysis, essentially all the nematodes present in the sample used collect at the bottom of the well, allowing for a more reliable and reproducible measurement of the signal generated by said sample (e.g. by measurement at the bottom of the well or along the central vertical axis of the well) . , Thus, in a first aspect, the invention relates to a method • for measuring/determining at least one signal generated by and/or associated with a sample of nematode worms, which nematode worms are kept in a suitable medium in a suitable vessel or container, said method comprising the steps of: exposing the sample of nematodes to at least one compound which paralyses or kills the nematodes present in the sample; and measuring/determining the at least one signal. In the method of the invention, the sample of nematodes can be kept - e.g. maintained, grown or incubated - in any suitable vessel or container, but is preferably kept in a well of a multi-well plate, such as standard 6, 24, 48, 96, 384, 1536, or 3072 well plates (in which each well of the multi-well plate may contain a separate sample of worms) . Such plates and general techniques and apparatus for maintaining/handling nematode worms in such multi-well plate format are well known in the art, for instance from the applications mentioned hereinabove.
The sample of nematodes may be kept in or on any suitable medium - including but not limited to solid and semi-solid media - but is preferably kept in a suitable liquid or viscous medium (e.g. with a viscosity at the temperature of the assay that is equal to a greater than the viscosity of M9 medium, as measured by a suitable technique, such as an Ubbelohde, Ostwald and/or Brookfield viscosimeter) . Again, suitable media for growing/maintaining nematode worms are well known in the art, for instance from the applications mentioned hereinabove, and include M9.
The sample of nematodes may comprise any suitable number of worms, depending on the size of the container/vessel used. Usually, the sample will comprise between 2 and 500, in preferably between 3 and 300, more preferably between 5 and 200, even more preferably between 10 and 100 nematodes. When the assay is carried out in multi-well plate format, each well usually contains between 15 and 75 worms, such as 20 to 50 worms. The medium may further contain all factors, compounds and/or nutrients required to carry out the assay and/or required for the survival, maintenance and/or growth of the worms. For this, reference is again made to the prior art, such as the applications referred to above. In one specific embodiment, the medium also contains a suitable source of food for the worms (such as bacteria) . This not only ensures/promotes survival and/or growth of the nematodes, but may also trigger or increase pharynx pumping by the nematodes, and may therefore facilitate assays based on and/or requiring (at least some degree of) pharynx pumping.
The at least one compound which paralyses the nematodes may be any suitable compound which (at the concentration added to the sample of nematodes) paralyses the worms, such that they collect at the bottom of the container. Preferably, said compound is chosen from Ethanol, methanol, DMSO, Levamisole, aldicarb, azide, trichlorphon, muscimole, carbosulfan, carbofuran, carbosasos, most preferably ivermectine. Also, it is not excluded to use a compound which (at the concentration added to the sample of nematodes) kills the nematodes, although this is generally not preferred.
The paralysing compound is added to the sample of nematode worms (e.g. to the medium/container or well containing said sample) in a concentration such that - due to the paralysing effect of the compound (and usually also due to gravity) - the worms collect at a specific part of the container or well, which is usually the part from which the signal of interest generated by/associated with the sample of nematodes is measured/determined. Usually this will be the bottom half, bottom part or bottom tip of the container or well. Suitable concentrations of paralysing compound may easily be determined by the skilled person, and - depending on the compound (s) used - may be between 0.01 and 10.000 micromolar, preferably between 0.1 and 1000 micromolar, in particular between 1 and 100 micromolar. For instance, for ivermectine, a suitable concentration will usually be between 0.5 and 50 micromolar, in particular between 1 and 10 micromolar, such as 3 micromolar.
In step b) above, the worms are exposed to the at least one paralysing compound for a time that is sufficient for the worms - due to the paralysing effect of the compound (and usually also due to gravity) - to collect at a specific part of the container or well, e.g. at the bottom of the well. Suitable exposure times may easily be determined by the skilled person, and - depending on the compound (s) used - may be between one minute and four hours, preferably between 5 minutes and two hours, more preferably between ten minutes and one hour, such as between 20 minutes and 45 minutes. Thereafter, the signal of interest generated by/associated with the sample of nematodes is measured/determined. This may be any suitable signal, such as fluorescence or another optical signal. These and other suitable signals, as well as for (automated) techniques for measuring them, reference is again made to the prior art, and in particular to the applications referred to hereinabove. Preferably said signal is measured by means of a non-visual detection technique, as described in the applications referred to above.
The method of the invention may be used to improve the reliability, reproducibility and/or robustness of any assay involving the use of nematode worms - and in particular nematode worms of the genus Caenorhabdi tis such as C. elegans or C. briggsae - such as the assays described in the applications mentioned above and other in other applications by applicant. As will be clear from the above, this may simply be achieved by adding to the method/protocol for carrying out said known assay, a step of adding the paralysing compound (i.e. step b) above), in the manner described above, and prior to measurement of the signal of interest. As will also be clear from the above, the invention is particularly suited as an improvement for such known assays when they are carried out in a multi-well plate format, in liquid or viscous medium, and/or in an automated fashion.
As will also be clear from the above, the invention may in particular be used to improve assays in which the effect of one or more compounds or other factors on (the signal generated by/associated with) the sample of nematode worms is determined, and some of these assays are also described in the applications referred to above. Generally, in such assays, the method of the invention will comprise the further step of: exposing the sample of nematode worms to at least one compound to be tested. The further conditions for this step a) - such as suitable concentrations of compound and times for such exposures - will depend on the specific assay used and on the compound (s) to be tested. Reference is again made to the prior art, such as the applications referred to above. The compounds may be tested at any suitable concentration or range of concentrations (e.g. to establish a dose response curve) . For example, suitable concentrations may be in the range of between 0.001 and 10.000 micromolar, preferably between 0.01 and 1000 micromolar, in particular between 0.05 and 500 micromolar, although the invention is not limited thereto.
Suitable contact times of the compound and the (sample of) nematodes may be between 10 seconds and 48 hours, preferably between 1 minute and 36 hours, and may for instance be between 30 minutes and 24 hours. For instance, incubation of about 1 hr to overnight (e.g. about 16 hours) may be used.
In a further aspect, the invention relates to the use of at least one paralysing compound - as described above - in improving the reliability, reproducibility and/or robustness of an assays involving the use of ( a sample of) nematode worms. In this aspect, the paralysing compound, its use and the assays involving the use of nematode worms are preferably as further described above. Experimental Part :
This methodology as described above has been applied to a variety of assays, which resulted in enhanced reproducible read-out. More particularly the method of the -invention has been applied as an improvement of the earlier described pharynx pumping assay (WO00/06327) , resulting in an improved assay method. In this aspect of the invention, a method is described to identify improved signal detection in multi-well assays, using dispensed nematodes, wherein prior to detecting a signal indicating pharynx pumping by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi-well plates.
An other application of this new invention related to the detection of the defecation rate, in which the improvement results in a method to identify improved signal detection in multi-well assays, using dispensed • nematodes, wherein prior to detecting a signal indicating defecation by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates.
In still another application of this new invention, the invention is applied to egg laying, in which the improvement results in a method to identify improved signal detection in multi-well assays, using dispensed nematodes, wherein prior to detecting a signal indicating egg laying by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates. In a further application of this new invention, the invention is applied to fatty acid uptake, and cholesterol uptake, in which the improvement results in a method to identify improved signal detection in multi- well assays, using dispensed nematodes, wherein prior to detecting a signal indicating for lipid uptake or cholesterol uptake by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi-well plates In a further application of this invention a method is described to identify genetic mutations, using nematode worms dispersed in multi-well assay plates, contacted with a mutagen, wherein prior to detecting a signal indicating phenotypic, physiologic, behavioral or biochemical changes by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi-well plates.
Methods to generate mutations in C. elegans have previously been described in "Methods in Cell Biology, Volume 48, ed. by Epstein and Shakes, Academic press".
The major disadvantage of these methods, is the laborious task to select for the desired mutants. The method described here allows to select in an efficient and fast way for a mutation with the desired phenotypic, physiologic, behavioral or • biochemical change. The detection methods are the same as these described above and refer to the pharynx pumping assay, the defecation assay, the egg laying assay, the fatty acid uptake assay. Finally, the further application of this invention is a method to identify RNAi knock-outs, using nematode worms dispersed in multi-well assay plates, are feeded with bacteria that express high quantities of dsRNA, wherein prior to detecting a signal indicating phenotypic, physiologic, behavioral or biochemical changes by non-visual detection means, a paralyzing chemical substance is added to the wells of the multi- well plates.

Claims

CLAIMS :
1. Method for measuring/determining at least one signal generated by and/or associated with a sample of nematode worms, which nematode worms are kept in a suitable medium in a suitable vessel or container, said method comprising the steps of: b) exposing the sample of nematodes to at least one compound which paralyses or kills the nematodes present in the sample; and c) measuring/determining the at least one signal.
2. Method according to claim 1, further comprising the step of: exposing the sample of nematode worms to at least one compound to be tested.
3. Method according to any of the preceding claims, in which the at least one paralysing compound is chosen from ethanol, methanol, DMSO, Levamisole, aldicarb, azide trichlorphon, muscimole, carbosulfan, carbofuran, carbosasos .
4. Method according to any of the preceding claims, in which the at least one paralysing compound is ivermectine.
5. Method according to any of the preceding claims, in which the sample of nematodes is exposed to at least one paralysing compound at a concentration of paralysing, compound (s) of 0.01 and 10.000 micromolar, preferably between 0.1 and 1000 micromolar, in particular between 1 and 100 micromolar.
6. Method according to any of the preceding claims, carried out in a liquid or viscous medium.
7. Method according to any of the preceding claims, carried out in a multi-well plate format.
8. Method according to any of the preceding claims, carried out in an automated fashion.
9. Use of at least one paralysing compound in improving the reliability, reprqducibility and/or robustness of an assays involving the use of ( a sample of) nematode worms.
10. Use according to claim 9, in which the paralysing compound is chosen from ethanol, methanol, DMSO, azide Levamisole, aldicarb, trichlorphon, muscimole, carbosulfan, carbofuran, carbosasos,
11. Use according to claim 9 or 10, in which the paralysing compound is ivermectine.
12. Use according to any of claims 9-11, in which the at least one paralysing compound used in a concentration 0.01 and 10 . 000 micromolar, preferably between 0.1 and 1000 micromolar, in particular between 1 and 100 micromolar.
PCT/IB2001/001058 2000-05-19 2001-05-21 Improved assay techniques using nematode worms Ceased WO2001088532A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001584877A JP2003533696A (en) 2000-05-19 2001-05-21 Improved assay using nematodes
EP01936742A EP1282816A2 (en) 2000-05-19 2001-05-21 Improved assay techniques using nematode worms
US10/276,453 US7083947B2 (en) 2000-05-19 2001-05-21 Assay techniques using nematode worms
AU2001262601A AU2001262601A1 (en) 2000-05-19 2001-05-21 Improved assay techniques using nematode worms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0012229.1 2000-05-19
GBGB0012229.1A GB0012229D0 (en) 2000-05-19 2000-05-19 Lipid uptake assays

Publications (2)

Publication Number Publication Date
WO2001088532A2 true WO2001088532A2 (en) 2001-11-22
WO2001088532A3 WO2001088532A3 (en) 2002-04-04

Family

ID=9891997

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2001/001061 Ceased WO2001088533A2 (en) 2000-05-19 2001-05-21 Lipid uptake assays
PCT/IB2001/001058 Ceased WO2001088532A2 (en) 2000-05-19 2001-05-21 Improved assay techniques using nematode worms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001061 Ceased WO2001088533A2 (en) 2000-05-19 2001-05-21 Lipid uptake assays

Country Status (8)

Country Link
US (1) US6703214B2 (en)
EP (2) EP1285269B1 (en)
JP (2) JP2004524803A (en)
AT (1) ATE288587T1 (en)
AU (2) AU2001262601A1 (en)
DE (1) DE60108746T2 (en)
GB (2) GB0012229D0 (en)
WO (2) WO2001088533A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213117A1 (en) * 2000-10-10 2002-04-22 Steven Farber High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds
WO2003100094A2 (en) * 2002-05-23 2003-12-04 Devgen Nv Method for determining the influence of a compound on cholesterol transport
US20060191023A1 (en) * 2002-10-09 2006-08-24 Gill Matthew S Automated method for high throughput screening of nematodes
EP1834180A2 (en) * 2004-12-15 2007-09-19 Schering Corporation Functional assays for cholesterol absorption inhibitors
WO2008150832A1 (en) * 2007-05-31 2008-12-11 Sanofi-Aventis Assay methods for identifying agents that modify the activity of nape-pld or abh4
JP5120889B2 (en) * 2008-06-12 2013-01-16 独立行政法人産業技術総合研究所 Boron dipyrromethane derivative and lipid peroxide measuring reagent using the same
CN102288749B (en) * 2011-07-28 2013-07-31 山东农业大学 Dipterex bionic enzyme linked immunosorbent detection method
GB201301043D0 (en) * 2013-01-21 2013-03-06 Chronos Therapeutics Ltd Method for assessing cell aging
EP2775302A1 (en) * 2013-03-08 2014-09-10 Assistance Publique - Hôpitaux de Paris Compound-carrier systems for assays in nematodes
CN108794518B (en) * 2018-04-04 2020-06-19 安徽师范大学 Organic conjugated molecular material with BODIPY as basic skeleton and preparation method thereof
CN109799295A (en) * 2019-01-28 2019-05-24 江南大学 A kind of sample-pretreating method for Caenorhabditis elegans metabonomic analysis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
WO1990009096A2 (en) * 1989-02-03 1990-08-23 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5338854A (en) * 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5583008A (en) * 1993-05-19 1996-12-10 Nemapharm, Inc. Rapid diagnostic procedure for ivermectin resistance
US6342379B1 (en) * 1995-06-07 2002-01-29 The Regents Of The University Of California Detection of transmembrane potentials by optical methods
US5994063A (en) * 1995-06-23 1999-11-30 Metzker; Michael L. Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogenous amplification/detection assays
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
US6114177A (en) * 1997-11-12 2000-09-05 Phytochem Technologies, Inc. Fluorometric assay for measurement of antioxidant activity
JP2002508507A (en) * 1997-12-18 2002-03-19 セプラコア インコーポレーテッド A method for simultaneous identification of novel biological targets and drug discovery lead structures
US6348321B1 (en) * 1998-01-15 2002-02-19 Whitehead Institute For Biomedical Research Methods of identifying agents inhibiting fatty acid transport proteins
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9908677D0 (en) 1999-04-15 1999-06-09 Devgen Nv Compound assay
JP2002542466A (en) 1999-04-15 2002-12-10 デフヘン・ナムローゼ・フェンノートシャップ Compound screening method
US6323186B1 (en) * 1999-09-17 2001-11-27 Molecular Probes, Inc. Phosphate-bound polyazaindacene derivatives of nucleotides

Also Published As

Publication number Publication date
JP2004524803A (en) 2004-08-19
WO2001088533A3 (en) 2002-05-16
GB2366615B (en) 2002-07-24
AU2001262601A1 (en) 2001-11-26
GB0012229D0 (en) 2000-07-12
US6703214B2 (en) 2004-03-09
GB0112360D0 (en) 2001-07-11
WO2001088532A3 (en) 2002-04-04
US20020137205A1 (en) 2002-09-26
JP2003533696A (en) 2003-11-11
GB2366615A (en) 2002-03-13
DE60108746T2 (en) 2006-03-30
EP1285269B1 (en) 2005-02-02
DE60108746D1 (en) 2005-03-10
WO2001088533A2 (en) 2001-11-22
AU2001264163A1 (en) 2001-11-26
EP1285269A2 (en) 2003-02-26
ATE288587T1 (en) 2005-02-15
EP1282816A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
Starkuviene et al. The potential of high‐content high‐throughput microscopy in drug discovery
Boyd et al. Caenorhabditis elegans as a model in developmental toxicology
US8268577B2 (en) Electrochemical methods of detecting colon cancer cells and use of same for diagnosing and monitoring treatment of the disease
Laine et al. Fast fluorescence lifetime imaging reveals the aggregation processes of α-synuclein and polyglutamine in aging Caenorhabditis elegans
WO2001088532A2 (en) Improved assay techniques using nematode worms
US20080267880A1 (en) Automated method for high throughtout screening of nematodes
Lo Vecchio et al. Spontaneous rotations in epithelia as an interplay between cell polarity and boundaries
WO2006084242A2 (en) Tissue sensor and uses thereof
Şen et al. A new electrochemical assay method for gene expression using HeLa cells with a secreted alkaline phosphatase (SEAP) reporter system
Legon et al. Genome-wide screens in yeast models towards understanding chronological lifespan regulation
HUP0201142A2 (en) Compound screening method
US7083947B2 (en) Assay techniques using nematode worms
WO2001094627A2 (en) Assay techniques based on growth stage dependent expression in c. elegans
Golden et al. Microarray analysis of variation in individual aging C. elegans: approaches and challenges
Jagadeesan et al. RNAi screening: automated high‐throughput liquid RNAi screening in Caenorhabditis elegans
EP2946359B1 (en) Method for assessing cell aging
Demir et al. Cell perturbation screens for target identification by RNAi
Patat et al. Trafficking in cancer: from gene deregulation to altered organelles and emerging biophysical properties
Giacomotto et al. Caenorhabditis elegans as a chemical screening tool for the study of neuromuscular disorders. Manual and semi-automated methods
Mimura et al. Cell-based multisensor array for detecting cancer biomarkers in human urine
EP1235925B1 (en) Feeding assay for identifying nematicidal compounds
WO2003100094A2 (en) Method for determining the influence of a compound on cholesterol transport
Artursson et al. In vitro characterization of interactions with drug transporting proteins
CA2417556C (en) Simple quantitative fluorescent assay method for determining the activity of transport proteins of interest
DE69934013D1 (en) TEST FOR THE DETECTION OF OXIDATIVE STRESS USING CELL SUSPENSIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001936742

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001936742

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10276453

Country of ref document: US